Comparable stake leader
Ken Takanashi
SEC ownership of Satsuma Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001692830.
Disclosed value leader
Ken Takanashi
Comparable rows
0/5
Latest evidence
06 Jun 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ken Takanashi
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
06 Jun 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001692830
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Satsuma Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ken Takanashi
Disclosed value leader
Ken Takanashi
Comparable rows
0/5
Latest evidence
06 Jun 2023
3/4/5
Highest disclosed value: $22,611,402
5 rows are not safely comparable across share classes.
Quick read
Ken Takanashi has the largest disclosed position value at $22.61M.
0 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ken Takanashi's linked filing trail.
Disclosed position value
Top 4
Ken Takanashi
$22.61M
Shin Nippon Biomedical Laboratori...
$10M
Braden M. Leonard
$6M
Commodore Capital LP
$325.7K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-5 of 5 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ken Takanashi |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$22,611,402
24,847,694 shares
|
— | 06 Jun 2023 |
| Shin Nippon Biomedical Laboratories, Ltd. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$9,995,906
10,984,512 shares
|
— | 06 Jun 2023 |
| Braden M. Leonard |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$5,996,900
6,590,000 shares
|
— | 21 Nov 2022 |
| Commodore Capital LP |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$325,668
461,286 shares
|
— | 14 Nov 2022 |
| Detlef Albrecht |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
190,000 shares
|
— | 03 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Satsuma Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Ken Takanashi
Net 12M change
$0
Latest report
08 Jun 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ken Takanashi | Director, 10%+ Owner | $22,611,402 | Filing P/S | 06 Jun 2023 | ||
| Shin Nippon Biomedical Laboratories, Ltd. | 10%+ Owner | $9,995,906 | Mixed | 06 Jun 2023 | ||
| Braden M. Leonard | 10%+ Owner | $5,996,900 | Mixed | 21 Nov 2022 | ||
| Commodore Capital LP | 10%+ Owner | $325,668 | Filing P/S | 14 Nov 2022 | ||
| Rajeev M. Shah | Director, 10%+ Owner | Mixed | 06 Jun 2023 | |||
| Mutya Harsch | Director | Mixed | 08 Jun 2023 | |||
| RA CAPITAL MANAGEMENT, L.P. | Former 10% Owner | Mixed | 08 Jun 2023 | |||
| Ph.D. Michael T. Riebe | Director | Mixed | 08 Jun 2023 | |||
| Heath Lukatch | Director | Mixed | 08 Jun 2023 | |||
| John A. Kollins | President and CEO, Director | Mixed | 06 Jun 2023 | |||
| Detlef Albrecht | Chief Medical Officer | Mixed | 03 Jun 2022 | |||
| Thomas P. O'Neil | Chief Financial Officer | Mixed | 06 Jun 2023 | |||
| Elisabeth Sandoval Little | Director | Mixed | 08 Jun 2023 | |||
| Thomas B. King | Director | Mixed | 08 Jun 2023 | |||
| Thomas P. Soloway | Director | Mixed | 08 Jun 2023 |
Recent insider transactions for Satsuma Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.